M&A Healthcare Advisors Brokers Sale of Innovo Detox to R&S Holdings
MAHA advised Pennsylvania-based Innovo Detox on its acquisition by R&S Holdings, marking another deal in the growing behavioral health sector.
M&A Healthcare Advisors (MAHA), a FINRA-licensed investment bank specializing in healthcare transactions, announced Monday it served as exclusive financial advisor to Innovo Detox in connection with the company's sale to R&S Holdings, Inc. The deal was disclosed October 12, 2026, from Los Angeles.
Innovo Detox is a Pennsylvania-based provider of substance use disorder (SUD) treatment and related drug and alcohol recovery services. The transaction adds to a growing pipeline of behavioral health acquisitions as private capital continues to flow into the addiction treatment sector, drawn by persistent demand and fragmented market conditions.
Read more Selling Commercial Property in Rural Maine: What Owners Should Know →
MAHA, which operates as a registered broker-dealer under FINRA oversight, positions itself as a niche advisor focused exclusively on healthcare industry deals. The firm's involvement underscores a broader trend of specialized investment banks playing an increasingly active role in consolidating smaller, regional behavioral health operators into larger platforms.
The substance use disorder treatment market has attracted significant transaction activity in recent years as payers, private equity firms, and strategic acquirers seek to build scaled networks capable of meeting rising demand for addiction services across the United States. Terms of the Innovo Detox transaction were not disclosed.
Continue reading at All Financial Services & Investing.
